Crown Bioscience and The Jackson Laboratory Collaboration Enables Global Access to FATZO Mouse Model
Continued Collaboration Facilitates Global Distribution of Obesity, Metabolic Disease, and NASH Model and Priority Supply to CrownBio’s World-Class Cardiovascular, Obesity, and Metabolic Disease Platform
San Diego, Calif. – March 5, 2019 - Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research today announced an exclusive agreement with The Jackson Laboratory (JAX) to utilize its world-class distribution channels to make the FATZO mouse model available to researchers globally.
As CrownBio’s exclusive distributor of the FATZO model, JAX, the independent, nonprofit biomedical research organization will utilize its expertise in the breeding, production, and delivery of high-quality mouse models to increase worldwide access with immediate effect. As part of the agreement, JAX will provide a prioritized model supply to support CrownBio’s global service platform in obesity, diabetes and associated indications.
A unique and proprietary model to CrownBio, the FATZO model, is a translationally-relevant, inbred polygenic mouse model ideal for the study of obesity, metabolic syndrome and diabetes, and drug development. The model is sensitive to developing obesity and metabolic syndrome under the influence of a high-fat diet, which has been demonstrated to be a significant factor in the human development of these conditions. The model also exhibits human-like disease progression, making it an ideal candidate for modeling human metabolic syndrome.
“I am excited that our ongoing relationship with The Jackson Laboratory has resulted in this agreement and will enable easier access to FATZO, thereby accelerating discovery in obesity, diabetes, and NAFLD/NASH,” said Dr. Jim Wang, senior vice president of Crownbio’ s Cardiovascular and Metabolic Disease division.
To learn more about the FATZO mouse and Crown’s Cardiovascular and Metabolic Disease platform, visit: www.crownbio.com/cvmd
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...